First-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy provide similar survival benefit for patients with metastatic colorectal cancer

Bookmark and Share
Published: 1 Jun 2014
Views: 2550
Rating:
Save
Dr Alan Venook - UCSF, San Francisco, USA

 At a press conference at ASCO 2014, Dr Venook presents the results from a large federally funded phase III study which demonstrate that four common first-line treatment regimens – bevacizumab plus chemotherapy and cetuximab plus chemotherapy – are equally effective for patients with metastatic colorectal cancer and no KRAS mutations.

Read the article for more.